Vyome Biosciences, a clinical-stage specialty biopharmaceutical company developing medicines for treating skin diseases caused by resistant microbes, has received $14 million (approx INR 93 crore) Series-C funding. The round was led by Perceptive Advisors, a New York based life sciences fund and, Romulus Capital, a Boston-based VC firm, along with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital. The funding will be utilized to advance the clinical development of lead product and continue to develop other proprietary products in the pre-clinical stage.